Company Description
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States.
The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment.
HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Dr. Hing C. Wong Ph.D. |
Contact Details
Address: 2929 N Commerce Pkwy Miramar, Florida 33025 United States | |
| Phone | 954-842-2024 |
| Website | hcwbiologics.com |
Stock Details
| Ticker Symbol | HCWB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001828673 |
| CUSIP Number | 40423R105 |
| ISIN Number | US40423R1059 |
| Employer ID | 82-5024477 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hing C. Wong Ph.D. | Founder, Chief Executive Officer, Director and Secretary |
| Rebecca Byam CPA, M.B.A. | Chief Financial Officer |
| Dr. Peter Rhode Ph.D. | Chief Scientific Officer and Vice President of Clinical Operations |
| Nicole Valdivieso Esq. | Vice President of Legal Affairs |
| Raquel Diaz M.S. | Director of Human Resources |
| Lee D. Flowers | Senior Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | 8-K | Current Report |
| Feb 27, 2024 | D | Notice of Exempt Offering of Securities |
| Feb 22, 2024 | 8-K | Current Report |
| Jan 12, 2024 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Nov 14, 2023 | 8-K | Current Report |
| Aug 31, 2023 | 8-K | Current Report |
| Aug 24, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |